Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_assertion type Assertion NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_head.
- NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_assertion description "[These findings provide a rationale for use of LRH-1 as immunotherapeutic target antigen to treat residual or persisting myeloid malignancies after allogeneic SCT.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_provenance.
- NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_assertion evidence source_evidence_literature NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_provenance.
- NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_assertion SIO_000772 19074734 NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_provenance.
- NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_assertion wasDerivedFrom befree-20150227 NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_provenance.
- NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_assertion wasGeneratedBy ECO_0000203 NP413258.RAYVweEuT2cBG2s7xNt2FOP6O1g4xlmjHVCAZsY55Tcgo130_provenance.